Delivery Order SPE2DB22D3010-SPE2DB25FP3HW
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 30, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $2,870.86 and is scheduled for completion by July 31, 2025. The award represents a child contract action under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $54,717.86 by the Defense Logistics Agency (DLA) on August 28, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract is characterized as a firm fixed price delivery order with an ultimate completion date of August 29, 2025, and was competitively awarded with no set-aside designation. This award is a child contract issued...
- The U.S. Defense Department's Medical Supply Chain awarded a $18.8K delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 21, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 20, 2025, by the Defense Logistics Agency for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL quantities, with a contract value of $11,350.99 and an ultimate completion date of August 21, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded through competitive procurement. The award represents a child order under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp was awarded a delivery order for Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials with a ceiling value of $12,533.20 by the Defense Logistics Agency on August 15, 2025. The contract is a firm fixed price delivery order with an ultimate completion date of August 18, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a child contract under...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract is valued at $3,759.96 and carries a firm fixed price with an ultimate completion date of August 19, 2025. The award utilized competitive procurement procedures with no set-aside designation. The place of performance is identified as the vendor's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a ceiling value of $18,294.14. This competitively awarded, firm fixed-price delivery order is set to be completed by July 31, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order valued at $36,378.29 for Ozempic 2 mg/dose (8 mg/3 mL) 3 mL vials from the Defense Medical Supply Chain on July 28, 2025. The contract is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, and was awarded on a competitive basis without set-aside designation. This delivery order represents a child contract executed under...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $1,566.67 by the Defense Logistics Agency (DLA) on August 1, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract utilizes firm fixed pricing with no set-aside designation, indicating it was competitively awarded. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $17,607.59 by the Defense Logistics Agency on August 12, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials. This competitively awarded contract utilizes firm fixed pricing with no set-aside designation and specifies an ultimate completion date of August 13, 2025. The delivery order is issued under AmerisourceBergen's larger...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP3HWDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on August 29, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3ml vials. The contract is valued at $19,050.96 and carries an ultimate completion date of September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle valued through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency. The company's role in this delivery order aligns with its broader contract portfolio supplying brand-name and generic medications, vaccines, and specialized healthcare commodities across multiple therapeutic domains to the Defense Health Agency and other government healthcare systems. The pharmaceutical distributor's award of this diabetes medication delivery reflects its established capability to fulfill federal medical supply requirements for military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.1k | 8/29/25 |